Search
BRG01
go.drugbank.com/drugs/DB18173InvestigationalBRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]
BNT111
go.drugbank.com/drugs/DB18177InvestigationalIt consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
LYT-200
go.drugbank.com/drugs/DB18179InvestigationalLYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
ATI-1013
go.drugbank.com/drugs/DB18185InvestigationalATI-1013 is a fully human nicotine-specific monoclonal antibody.
EDI-200
go.drugbank.com/drugs/DB18188InvestigationalEDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
AGuIX
go.drugbank.com/drugs/DB18189InvestigationalIt is under development as a radiosensitizer to be used during radiation treatment of malignant glioma. … AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates.
CLBS12
go.drugbank.com/drugs/DB18192InvestigationalCLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.
GX-G8
go.drugbank.com/drugs/DB18196ExperimentalGX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
ST-003
go.drugbank.com/drugs/DB18197ExperimentalST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Synonyms: Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu- Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2, L-Alaninamide, glycyl-L-tryptophyl-L-threonyl-L-leucyl-L-asparaginyl-L-seryl-L-alanylglycyl-L-tyrosyl-L-leucyl-L-leucylglycyl-L-prolyl-L-prolyl-L-prolyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-FCX-013
go.drugbank.com/drugs/DB18218InvestigationalFCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).